IPA
IPA
ImmunoPrecise Antibodies Ltd. • NASDAQ
$1.62 ▲ 2.53% (+0.04)
Market Cap $74.77 M
52w High $3.25
52w Low $0.27
Dividend Yield 0%
P/E -2.4545454545454546
Volume 55.66K
Outstanding Shares 46.15M
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $3.161M ▼ | $5.68M ▼ | $-2.959M ▼ | -93.61% ▼ | $-0.07 ▼ | $-3.211M ▼ |
| Q4-2025 | $6.981M ▲ | $5.918M ▼ | $-2.161M ▲ | -30.955% ▲ | $-0.065 ▲ | $-988K ▲ |
| Q3-2025 | $6.151M ▲ | $6.588M ▲ | $-21.521M ▼ | -349.878% ▼ | $-0.66 ▼ | $-22.967M ▼ |
| Q2-2025 | $6.125M ▲ | $6.256M ▼ | $-2.553M ▲ | -41.682% ▲ | $-0.091 ▲ | $-1.524M ▲ |
| Q1-2025 | $5.263M | $6.982M | $-3.999M | -75.983% | $-0.15 | $-3.378M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $32.435M ▲ | $40.748M ▼ | $20.005M ▼ | $20.743M ▼ |
| Q4-2025 | $10.665M ▼ | $44.441M ▼ | $20.815M ▲ | $23.626M ▼ |
| Q3-2025 | $12.915M ▲ | $45.534M ▼ | $20.41M ▼ | $25.124M ▼ |
| Q2-2025 | $3.534M ▼ | $59.963M ▲ | $27.286M ▲ | $32.677M ▼ |
| Q1-2025 | $3.913M | $59.299M | $26.445M | $32.854M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-2.959M ▼ | $-4.213M ▼ | $-594K ▼ | $-371K ▲ | $-5.767M ▼ | $-4.495M ▼ |
| Q4-2025 | $-2.161M ▲ | $-1.14M ▲ | $-359K ▼ | $-418K ▼ | $-2.214M ▼ | $-1.499M ▼ |
| Q3-2025 | $-21.521M ▼ | $-1.203M ▲ | $-112K ▼ | $10.546M ▲ | $9.384M ▲ | $-1.315M ▲ |
| Q2-2025 | $-2.553M ▲ | $-2.243M ▼ | $-65K ▲ | $2.069M ▼ | $-379K ▼ | $-2.308M ▼ |
| Q1-2025 | $-3.999M | $-1.824M | $-263K | $2.696M | $455K | $-2.087M |
Revenue by Products
| Product | Q3-2024 |
|---|---|
 Product Sales | $0 ▲ |
 Project Revenue | $20.00M ▲ |
Market Cap $74.77 M
52w High $3.25
52w Low $0.27
Dividend Yield 0%
P/E -2.4545454545454546
Volume 55.66K
Outstanding Shares 46.15M
About ImmunoPrecise Antibodies Ltd.
https://www.ipatherapeutics.comImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $3.161M ▼ | $5.68M ▼ | $-2.959M ▼ | -93.61% ▼ | $-0.07 ▼ | $-3.211M ▼ |
| Q4-2025 | $6.981M ▲ | $5.918M ▼ | $-2.161M ▲ | -30.955% ▲ | $-0.065 ▲ | $-988K ▲ |
| Q3-2025 | $6.151M ▲ | $6.588M ▲ | $-21.521M ▼ | -349.878% ▼ | $-0.66 ▼ | $-22.967M ▼ |
| Q2-2025 | $6.125M ▲ | $6.256M ▼ | $-2.553M ▲ | -41.682% ▲ | $-0.091 ▲ | $-1.524M ▲ |
| Q1-2025 | $5.263M | $6.982M | $-3.999M | -75.983% | $-0.15 | $-3.378M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $32.435M ▲ | $40.748M ▼ | $20.005M ▼ | $20.743M ▼ |
| Q4-2025 | $10.665M ▼ | $44.441M ▼ | $20.815M ▲ | $23.626M ▼ |
| Q3-2025 | $12.915M ▲ | $45.534M ▼ | $20.41M ▼ | $25.124M ▼ |
| Q2-2025 | $3.534M ▼ | $59.963M ▲ | $27.286M ▲ | $32.677M ▼ |
| Q1-2025 | $3.913M | $59.299M | $26.445M | $32.854M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-2.959M ▼ | $-4.213M ▼ | $-594K ▼ | $-371K ▲ | $-5.767M ▼ | $-4.495M ▼ |
| Q4-2025 | $-2.161M ▲ | $-1.14M ▲ | $-359K ▼ | $-418K ▼ | $-2.214M ▼ | $-1.499M ▼ |
| Q3-2025 | $-21.521M ▼ | $-1.203M ▲ | $-112K ▼ | $10.546M ▲ | $9.384M ▲ | $-1.315M ▲ |
| Q2-2025 | $-2.553M ▲ | $-2.243M ▼ | $-65K ▲ | $2.069M ▼ | $-379K ▼ | $-2.308M ▼ |
| Q1-2025 | $-3.999M | $-1.824M | $-263K | $2.696M | $455K | $-2.087M |
Revenue by Products
| Product | Q3-2024 |
|---|---|
| Product Sales | $0 ▲ |
| Project Revenue | $20.00M ▲ |
CEO
Jennifer Lynne Bath
Compensation Summary
(Year 2024)
Salary $0
Bonus $0
Stock Awards $0
Option Awards $0
Incentive Plan Pay $0
All Other Compensation $0
Outstanding Value $0
Total Compensation (Unknown At The Moment)
CEO
Jennifer Lynne Bath
Compensation Summary
(Year 2024)
Salary $0
Bonus $0
Stock Awards $0
Option Awards $0
Incentive Plan Pay $0
All Other Compensation $0
Outstanding Value $0
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public January 7, 2002
Method of going public IPO
Full time employees 72
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-11-23 | Reverse | 1:5 |
| 2017-01-03 | Reverse | 1:3 |
| 2016-09-02 | Reverse | 1:3 |
| 2013-05-30 | Forward | 4:1 |
| 2013-04-12 | Forward | 4:1 |
| 2011-10-14 | Reverse | 1:10 |
| 2011-09-13 | Reverse | 1:10 |
Most Recent Analyst Grades
Grade Summary
Buy 1
Speculative Buy 1
Institutional Ownership
MARSHALL WACE NORTH AMERICA L.P.
23.1K Shares
$37.422K
IFP ADVISORS, INC
20K Shares
$32.4K
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
0 Shares
$0
Summary
% Of Shares Owned 0.09%
Total Number Of Holders 3
Only Showing The Top 3